IMM Chart, page-16

Joe, not sure on 761 mate......more looking at keytruda/efti compatibility success rate and thus, worth....

Immutep are essentially a company not earning a cent at this stage that will support ongoing research

without assistance.....Ergo, two recent patent applications for combo trials successful, Efti is our strength,

thus our core value.....Big Pharma are increasingly leaving R&D to speciality contractors of which Immutep

is, in the Lag-3 gene field......Efti is a proven monocyte stimulant(melanoma) which are essential to improve

keytruda's success rate.....

Immutep have set themselves up playing to their strength and the lure of Merck being able to extend their

keytruda patent expiry date in various cancer combo disciplines just might be too much for them to pass up.

Just my thinking and not much more....